Lekovic, Danijela (36659562000)Danijela (36659562000)LekovicBogdanovic, Andrija (6603686934)Andrija (6603686934)BogdanovicArsenovic, Isidora (58551558700)Isidora (58551558700)ArsenovicIvanovic, Jelena (58551445800)Jelena (58551445800)IvanovicCvetkovic, Mirjana (58716866000)Mirjana (58716866000)CvetkovicJovanovic, Jelica (57202914654)Jelica (57202914654)JovanovicČolović, Nataša (6701607753)Nataša (6701607753)ČolovićLucijanic, Marko (36082720300)Marko (36082720300)LucijanicKrečak, Ivan (57190584995)Ivan (57190584995)Krečak2025-06-122025-06-122025https://doi.org/10.1080/10428194.2025.2503458https://www.scopus.com/inward/record.uri?eid=2-s2.0-105005406674&doi=10.1080%2f10428194.2025.2503458&partnerID=40&md5=97c061e18ff687feb2ee34b594ce054chttps://remedy.med.bg.ac.rs/handle/123456789/720Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x109/L) absolute neutrophil and low(<1.7 × 109/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability. © 2025 Informa UK Limited, trading as Taylor & Francis Group.